Lymphoma, B-Cell: Clinical Trials

28 trials for Lymphoma, B-Cell, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

9 unknown, 8 recruiting, 6 completed, 3 not yet recruiting. 28 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 428Unknown 9, Recruiting 8, Completed 6, Not yet recruiting 3, Active not recruiting 1, Terminated 1

Follow Lymphoma, B-Cell: new trials by email Literature Review of Lymphoma, B-Cell trials Research Report on Lymphoma, B-Cell

Trials (filtered) newest first · largest first

All 28 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Efficacy and Safety of Polatuzumab Vedotin, Rituximab Combined With Reduced-dose Cyclophosphamide, Doxorubicin and Prednisone Regimen in the Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma: A Multicenter, Single-arm, Prospective Study
Polatuzumab Vedotin, Rituximab, Cyclophosphamide - Diffuse Large B-Cell Lymphoma
Phase 4RecruitingThe First Hospital of Jilin University262026-10-152026-11-02
Pomalidomide Plus Rituximab Maintenance in Young High-Risk Newly Diagnosed DLBCL After First-Line Response
Pomalidomide, Rituximab - Diffuse Large B-Cell Lymphoma (DLBCL)
Phase 4Not yet recruitingThe First Hospital of Jilin University272026-09-012026-08-12
Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma
Orelabrutinib - Marginal Zone Lymphoma(MZL)
Phase 4RecruitingBeijing Tongren Hospital882025-11-252026-01-21
Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma
Rituximab, Zanubrutinib - Hemophagocytic Lymphohistiocytosis, B Cell Lymphoma
Phase 4RecruitingThe First Affiliated Hospital of Soochow University402025-11-012025-12-08
Efficacy and Safety of Chidamide Combined With PD-1 Inhibitor as Maintenance Therapy Following CAR-T Cell Treatment With TP53-Mutated Large B-Cell Lymphoma (LBCL)
chidamide+PD-1 inhibitor - Large B-Cell Lymphoma (LBCL), Lymphoma, Large B-Cell, Diffuse
Phase 4RecruitingShanghai Tongji Hospital, Tongji University School of Medicine202025-10-302026-11-16
Glofitamab for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma
Glofitamab treatment - B Cell Lymphoma (BCL)
Phase 4Not yet recruitingZhengzhou University402025-05-302025-05-02
Axicabtagene Ciloleucel for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma
Axicabtagene Ciloleucel - Lymphoma, B-Cell
Phase 4RecruitingZhengzhou University202024-09-302024-10-15
A Study of Secondary Infusion of Relmacabtagene Autoleucel Injection for Relapsed or Refractory B-cell Lymphoma
Relmacabtagene Autoleucel Injection - Relapsed or Refractory B-cell Lymphoma
Phase 4Not yet recruitingChanghai Hospital132023-06-202023-06-15
Secondary Infusion of Relma-cel Injection for Relapsed or Refractory B-cell Lymphoma
Relma-cel - Relapsed or Refractory B-cell Lymphoma
Phase 4RecruitingRuijin Hospital82023-05-012024-10-23
Selinexor Combined With R-GemOx as Second-line Treatment in Patients With Diffuse Large B-cell Lymphoma
selinexor - Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Phase 4UnknownChongqing University Cancer Hospital322023-02-282023-03-28
Clinical Study of OR for Second-line Treatment of Refractory MZL
Orelabrutinib combined with rituximab - OR Regimen for Relapsed/Refractory Marginal Zone Lymphoma
Phase 4RecruitingLixia Sheng392023-01-022024-06-11
B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021
Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Ifosfamide, Methotrexate, Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Ifosfamide, Methotrexate, Vincristine, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin hydrochloride, Etoposide, Ifosfamide, Methotrexate, vincristine - Non-hodgkin Lymphoma,B Cell, Burkitt Lymphoma
Phase 4RecruitingFederal Research Institute of Pediatric Hematology, Oncology and Immunology3002022-05-252022-08-26
Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting
Telemedicine Visit, Vital sign measurements, Out-Patient Clinic Visit - Large B-cell Lymphoma, Diffuse Large B-cell Lymphoma
Phase 4CompletedVanderbilt-Ingram Cancer Center252021-12-022025-03-27
R2 and Combination Chemotherapy Versus R and Combination Chemotherapy in Newly Diagnosed Highly Aggressive B-NHL
R2-combination chemotherapy, R-combination chemotherapy - Lymphoma, B-Cell
Phase 4UnknownShandong Provincial Hospital2002019-06-052019-11-05
A Clinical Trial of Decitabine in Relapse and Refractory Diffuse Large B Cell Lymphoma
Decitabine - Diffuse Large B Cell Lymphoma
Phase 4UnknownMingzhi Zhang602018-06-012018-09-14
Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma
(R)-CHOP regimen, (R)-CVP regimen - Diffuse Large B Cell Lymphoma
Phase 4UnknownMingzhi Zhang202017-07-012018-05-01
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
Ibrutinib - Lymphoma, B-Cell, Lymphoma, Non-Hodgkin
Phase 4Active not recruitingPharmacyclics Switzerland GmbH2972017-05-222025-10-30
Apatinib for Relapsed and Refractory Diffuse Large B Cell Lymphoma
Apatinib - Relapsed and Refractory, Diffuse Large B Cell Lymphoma
Phase 4CompletedZhengzhou University322017-01-012019-07-25
Anti-CD19:TCRζ Chimeric Antigen Receptor-T Cells in the Treatment for CD19+ B Cell Lymphoma
IL-2 pre-treated CD19 cells, IL-7/IL-15 pre-treated CD19 cells - Lymphoma, B Cell
Phase 4Unknownjiangjingting102016-12-012016-12-14
PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia
rhG-CSF regimen, Pegylated rhG-CSF regimen - Lymphoma,Non-Hodgkin
Phase 4UnknownShandong Provincial Hospital2402016-11-012016-12-19

Showing 20 of 28. Sign in to see all of them.

Narrower conditions

Lymphoma, Large B-Cell, Diffuse (14)  ·  Burkitt Lymphoma (5)  ·  Recurrence (5)  ·  Lymphoma, Non-Hodgkin (4)  ·  Lymphoma, B-Cell, Marginal Zone (3)  ·  Graft vs Host Disease (2)  ·  Hodgkin Disease (2)  ·  Lymphoma (2)  ·  Lymphoma, T-Cell (2)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (2)  ·  Anemia (1)  ·  Blast Crisis (1)  ·  Dendritic Cell Sarcoma, Interdigitating (1)  ·  HIV Infections (1)

Broader conditions

Hemic and Lymphatic Diseases (28)  ·  Immune System Diseases (27)  ·  Immunoproliferative Disorders (27)  ·  Lymphatic Diseases (27)  ·  Lymphoproliferative Disorders (27)  ·  Neoplasms (27)  ·  Neoplasms by Histologic Type (27)  ·  Lymphoma (26)  ·  Lymphoma, Non-Hodgkin (24)  ·  Infections (6)  ·  Virus Diseases (6)  ·  DNA Virus Infections (5)  ·  Disease Attributes (5)  ·  Epstein-Barr Virus Infections (5)

Interventions

Rituximab (7)  ·  Cyclophosphamide (6)  ·  Doxorubicin (3)  ·  Vincristine (3)  ·  Cytarabine (2)  ·  Dexamethasone (2)  ·  Etoposide (2)  ·  Ifosfamide (2)  ·  Methotrexate (2)  ·  Prednisone (2)  ·  axicabtagene ciloleucel (2)  ·  relmacabtagene autoleucel (2)  ·  Antilymphocyte Serum (1)  ·  Antiretroviral Therapy, Highly Active (1)  ·  Blood Pressure (1)

Sponsors

Mingzhi Zhang (3)  ·  Zhengzhou University (3)  ·  Ruijin Hospital (2)  ·  Shandong Provincial Hospital (2)  ·  The First Hospital of Jilin University (2)  ·  Beijing Tongren Hospital (1)  ·  Changhai Hospital (1)  ·  Chongqing University Cancer Hospital (1)  ·  Federal Research Institute of Pediatric Hematology, Oncology and Immunology (1)  ·  Lixia Sheng (1)  ·  Millennium Pharmaceuticals, Inc. (1)  ·  Nicola Goekbuget (1)  ·  PETHEMA Foundation (1)  ·  Pharmacyclics Switzerland GmbH (1)  ·  Seoul National University Hospital (1)

Countries

China (17)  ·  Spain (3)  ·  United States (3)  ·  Czechia (2)  ·  France (2)  ·  Germany (2)  ·  Poland (2)  ·  Russia (2)  ·  South Korea (2)  ·  Turkey (Türkiye) (2)  ·  Australia (1)  ·  Canada (1)  ·  Hungary (1)  ·  Italy (1)  ·  Malaysia (1)

Top investigators

Barry R. Meisenberg, MD (1)  ·  Jingting Jiang, Professor (1)  ·  Kevin Wu (1)  ·  Li Chen (1)  ·  Liang Wang, MD (1)  ·  Mingzhi Zhang (1)  ·  Mingzhi Zhang, Dr (1)  ·  Nicola Goekbuget, Dr. med. (1)  ·  Olalekan Oluwole, MD (1)  ·  Oriol Albert, Dr (1)  ·  Ribera Josep M, Dr (1)

Results publications

PMID 16648042, PMID 19219604, PMID 20660832, PMID 23615461, PMID 23753028, PMID 25359988, PMID 25934708, PMID 26808342, PMID 29155058, PMID 29437609, PMID 29610030, PMID 29654631, PMID 30881137, PMID 31733578, PMID 32158186, PMID 32487143, PMID 32589977, PMID 33002134, PMID 33148342, PMID 33202794, PMID 33764240, PMID 34222013, PMID 35240677, PMID 37173224, PMID 37403255, PMID 37463687, PMID 38578828, PMID 39272927, PMID 39853608, PMID 7477169

NIH funding

2016 (1)